Birigwa Christopher

Dr. Birigwa Christopher


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Frontiers in Aging
Verified
Journal Article
Open access
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
QTQiang Tong
Qiang Tong
BQBing Qu
Bing Qu
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
JLJianfei Luo
Jianfei Luo
Researchers now see aging as a process shaped by the interactions among metabolism, epigenetics, and hormones. Recent studies suggest that gut microbes play an important role in this system by making metabolites that can affect gene expression and chromatin structure. Still, it is not fully clear how gut microbes and the body influence each other as we age, since both are constantly changing. This review brings together current research on how metabolites from gut microbes—such as short-chain fatty acids, bile acids, tryptophan derivatives, and polyamines—affect the body’s epigenetic machinery through processes such as DNA methylation, histone modifications, and chromatin remodeling. We examine evidence from cell studies, animal experiments, and human research to assess the strength of the links and distinguish direct effects on chromatin from indirect metabolic or gene-expression changes. We focus especially on endocrine and reproductive organs, such as the hypothalamus, pancreas, liver, fat tissue, and cells that support the gonads, where signals from gut microbes overlap with hormonal control and metabolism. In these tissues, microbial metabolites influence key pathways related to inflammation, mitochondria, and nutrient sensing, but there is still little direct evidence in humans. The review also points out differences between lab models and what is observed in patients, highlighting the need for further work to apply these findings in real-world settings. Interactions between gut microbes and epigenetics form a two-way link between metabolism, immunity, and aging of the endocrine system. While more evidence shows that microbial metabolites can shape gene activity and epigenetic patterns, most of what we know comes from animal studies rather than direct tests in people. Moving forward, researchers will need to use broad, long-term studies that combine different types of data to figure out cause and effect and which tissues are involved. Understanding this system better could help create new biomarkers and treatments to influence aging by targeting the microbiome and its effects on epigenetics.

6 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
BQBing Qu
Bing Qu
YTYong-Qing Tong
Yong-Qing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
Background: Detection of colorectal cancer (CRC) currently relies mainly on invasive procedures such as colonoscopy. In experimental models, tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling. Building on these published insights, this study evaluated whether a panel of biomarkers previously associated with hypoxia-related processes, plasma methylated SEPT9 (mSEPT9), urinary N1, N12-diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, and LMR)—could be combined into a non-invasive diagnostic panel and compared with standard serum tumor markers. This study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. This study was conducted in a clinical diagnostic setting (patients with confirmed CRC, polyps, or benign surgical conditions) and does not represent a population-based screening cohort. Limitations include the lack of an external validation cohort; all analyses were performed on a single dataset, and the reported performance metrics may be optimistic. Independent validation is required before clinical implementation. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, and AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable logistic regression. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905). Conclusions: A multimarker panel of biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a non-invasive diagnostic approach for CRC detection in a clinical case–control setting. Validation in asymptomatic screening populations is required before any screening claim can be made. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes was not obtained and requires future investigation.

30 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
BQBing Qu
Bing Qu
YTYong-Qing Tong
Yong-Qing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
Background: Early detection of colorectal cancer (CRC) still relies mainly on invasive screening. Tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling in experimental models. Building on these insights, this study evaluated whether hypoxia pathway biomarkers—plasma methylated SEPT9 (mSEPT9), urinary N¹, N¹² diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, LMR)—could be combined into a noninvasive diagnostic panel compared with standard serum tumor markers. The study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable modeling. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905).” Conclusions: A multimarker panel of previously reported hypoxia-associated biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a scalable, noninvasive approach for CRC detection with high diagnostic accuracy. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes in patients was not obtained and requires future investigation.

6 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JLJianfei Luo
Jianfei Luo
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
YTYongqing Tong
Yongqing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
BackgroundEarly detection of colorectal cancer (CRC) still relies mainly on invasive screening. Tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia‑inducible factor (HIF) signaling in experimental models. Building on these insights, this study evaluated whether hypoxia‑pathway biomarkers—plasma methylated SEPT9 (mSEPT9), urinary N¹,N¹²‑diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, LMR)—could be combined into a non‑invasive diagnostic panel compared with standard serum tumor markers. The study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. MethodsThis prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable modeling.ResultsmSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19‑9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early‑stage CRC (AUC 0.905).”ConclusionsA multimarker panel of previously reported hypoxia‑associated biomarkers (mSEPT9, DiAcSpm, NLR, PLR, LMR) provides a scalable, non‑invasive approach for CRC detection with high diagnostic accuracy. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes in patients was not obtained and requires future investigation.